

## von Willebrand Factor Concentrates

Manufacturer	Product	Type	Indication
CSL Behring	<b>Humate-P®</b>	Plasma-derived FVIII/VWF complex. Average ratio of VWF:RCo to FVIII is 2.4:1.	Control of bleeding in adults and children with severe type 3 VWD; and patients with mild to moderate VWD where the response to desmopressin (DDAVP) is known or suspected to be inadequate. Not indicated for prophylaxis.
Grifols	<b>Alphanate®</b>	Plasma-derived FVIII/VWF complex. Ratio of VWF:RCo to FVIII is 1.3:1 (varies by lot).	Control and prevention of bleeding in adults and children with hemophilia A; and adults and children with VWD where the response to desmopressin (DDAVP) is known or suspected to be inadequate. Not indicated for patients with type 3 VWD undergoing major surgery.
Octapharma	<b>wilate®</b>	Plasma-derived FVIII/VWF complex. Ratio of VWF:RCo to FVIII is 1:1.	Control of bleeding in adults and children with type 3 VWD; and patients with mild to moderate VWD where the response to desmopressin (DDAVP) is known or suspected to be inadequate. Not indicated for prophylaxis for VWD. Indicated for control of bleeding in adolescents and adults with hemophilia; prophylaxis; and on-demand treatment.
Takeda	<b>Vonvendi®</b>	Recombinant VWF (contains no FVIII)	Control of bleeding in adults with VWD. Contains VWF only, no FVIII. Administer first dose with a recombinant FVIII-only product if FVIII baseline levels are below 40% or are unknown (this applies to all type 3 VWD patients).

VWD: von Willebrand disease. VWF: von Willebrand factor. RCo: ristocetin cofactor. VWF:RCo: von Willebrand factor ristocetin cofactor assay.  
 aPCC: activated prothrombin complex concentrate. © 2019 LA Kelley Communications, Inc. All rights reserved.

## Additional von Willebrand Disease Medicines

Manufacturer	Product	Type	Indication
Akorn	<b>Amicar®</b> (brand name for epsilon aminocaproic acid [EACA]); available as injection, oral solution, or tablets	Antifibrinolytic	Helps retain blood clots by inhibiting the action of enzymes that break down clots (fibrinolysis). Antifibrinolytics do not help form clots and are useful only in type 3 VWD after infusion of FVIII/VWF concentrate. Useful for mucous membrane bleeds, as in the mouth or nose, where clots are quickly broken down. Oral solution may also be used as a mouthwash. Short-term use (less than 10 days).
CSL Behring	<b>Stimate™</b> (desmopressin acetate nasal spray)	Synthetic form of natural hormone vasopressin	Indicated only for type 1 VWD with factor VIII levels greater than 5%; not for infants. Increases circulating levels of FVIII and VWF by releasing stores from endothelial cells lining blood vessels. Short-term use (a few days). Each subsequent use within 48 hours results in a lower response. Full response usually restored about a week after last use, but some patients may take up to 6 weeks after last use for stores of factor VIII and VWF to be replaced. Do not use if you have severe kidney disease or have ever had hyponatremia (low sodium levels).
Ferring Pharmaceuticals	<b>DDAVP® Injection</b> (desmopressin acetate)	Synthetic form of natural hormone vasopressin	Indicated only for type 1 VWD factor with VIII levels greater than 5%; for ages over 3 months. Increases circulating levels of FVIII and VWF by releasing stores from endothelial cells lining blood vessels. Short-term use (a few days). Each subsequent use within 48 hours results in a lower response. Full response usually restored about 1 week after last use, but some patients may take up to 6 weeks after last use for stores of factor VIII and VWF to be replaced. Do not use if you have severe kidney disease or have ever had hyponatremia (low sodium levels).
Ferring Pharmaceuticals	<b>Lysteda™</b> (brand name for tranexamic acid [TXA] tablets)	Antifibrinolytic	Helps retain blood clots by inhibiting the action of enzymes that break down clots. Indicated for heavy menstrual bleeding in women with VWD. Short-term use (less than 8 days) during menstrual period.
Pfizer	<b>Cyklokapron® Injection</b> (brand name for	Antifibrinolytic	Helps retain blood clots by inhibiting the action of enzymes that break down clots. Not indicated for use in VWD patients, but widely used off-label in VWD patients. 10 times more potent than Amicar. Short-term use (less than 8 days).

	tranexamic acid [TXA])		
--	---------------------------	--	--